Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFx-Hu2.0 in unresectable stage III/IV cutaneous melanoma
NCT03655756Phase 1Completed
- Sponsor
- TuHURA Biosciences, Inc.
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IFx-Hu2.0 in cutaneous melanoma (CM), sponsored by TuHURA Biosciences, Inc. Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs) at 28 days. Started Nov 2018; status: completed.
02
Drugs
IFx-Hu2.0
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03655756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655756.